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Abstract
The link between inflammation and colorectal carcinoma has been acknowledged. However, the impact of bacterial
lipopolysaccharide (LPS) binding to Toll-like receptor 4 (TLR4) on chemokine receptors in human colorectal carcinoma cells
still remains to be elucidated. The present study shows that exposure to LPS elevated CXC chemokine receptor 7 (CXCR7)
expression in colorectal carcinoma SW480 and Colo 205 cell lines expressing TLR4/myeloid differential protein (MD-2).
CXCR7 is associated with SW480 cell proliferation and migration. However, exposure of SW480 and Colo 205 cells to LPS had
no effect on CXCR4 expression. To further support the above results, the expression of TLR4, MD-2, and CXCR7 was analyzed
in human colorectal carcinoma tissues. Higher rates of TLR4 (53%), MD-2 (70%), and CXCR7 (29%) expression were found in
colorectal carcinoma tissues than in normal tissues. We demonstrated that the recombination of TLR4, MD-2 and CXCR7
strongly correlated with tumor size, lymph node metastasis and distant metastasis in colorectal carcinoma tissue samples
(p=0.037, p=0.002, p=0.042, resp.). Accordingly, simultaneous examination of the expression of TLR4, MD-2 and CXCR7 in
cancer tissues of colorectal carcinoma may provide valuable prognostic diagnosis of carcinoma growth and metastasis.
Interplay of TLR4, MD-2 and CXCR7 may be of interest in the context of novel immunomodulatory therapies for colorectal
carcinoma.
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Introduction
Colorectal carcinoma is one of the most common cancers,
which accounts for almost half a million deaths annually
worldwide. Death of these patients results from uncontrolled
metastatic disease, including liver, lymph nodes, or peritoneum
metastases. Inflammation is considered a risk factor for many
common malignancies including cancers of the lung [1], breast
[2], and colorectum [3]. Chronic inflammatory bowel disease
(IBD) such as chronic ulcerative colitis and Crohn’s disease is
associated with increased incidence of colorectal carcinoma as
compared with the normal population [4–5]. The link between
inflammation and colorectal carcinoma offers the possibility of
identifying novel ways to prevent cancer. However, the molecular
mechanisms whereby chronic inflammation predisposes to cancer
remain elusive.
Different products of enterobacteriaceae and especially their
lipopolysaccharides (LPS) may also contribute to perpetuation of
the chronic colorectal inflammation [6]. Toll-like receptor 4
(TLR4), which is responsible for recognizing Gram-negative
bacterial LPS, is upregulated and overexpressed in patients with
IBD or colorectal carcinoma [7–8] whereas TLR4 normally is
expressed at low level in the intestinal mucosa [1,5,9]. TLR4 is
known to be implicated in the pathogenesis of chronic gastroin-
testinal disorders such as celiac disease [10] and IBD [11].
Additionally, TLR4 elicits appropriate immune activation in
various types of cancer such as lung, ovary, stomach and
colorectum. LPS binding induces the formation of a symmetric
M-shaped TLR4-MD-2-LPS multimer composed of two copies of
the complex to activate pro-inflammatory signaling pathways,
which could induce expression of some chemoattractant receptors
[12–13]. Nevertheless, little else is known of the involvement of
TLR4 in the progression of colorectal carcinoma.
Initiation and progression of malignancies is the result of a
series of complex processes that depend upon multiple and
interactive factors [14]. Clinical and experimental studies indicate
that CXC chemokines enhance immunity to tumor-associated
antigens. However, they may also promote angiogenesis,
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1)/CXCR4 axis [15]. Recently, CXCR7 was identified as a
second receptor for CXCL12. It was described to be present on
the surface of many tumor cell types and on activated endothelial
cells. Generally, but depending on cell type, CXCR7 was
reported to be either a non-signaling receptor (decoy receptor)
or a signaling receptor. However, the function and regulatory
mechanisms of CXCR4/CXCR7 and the relationship between
TLR4-MD-2 and CXCR4/CXCR7 in colorectal carcinoma is
still unknown.
Our studies suggest that exposure to LPS elevates CXCR7
expression in a colorectal carcinoma SW480 and Colo 205 cell
lines expressing TLR4/MD-2. Meanwhile, CXCR7/CXCL12
modulates tumor cell proliferation and migration. However,
exposure of SW480 and Colo 205 cells to LPS had no effect on
CXCR4 expression. Exposure of HT-29 cells with expression of
only TLR4 to LPS had no effect on CXCR7 or CXCR4
expression. Furthermore, we found that combined expression of all
three markers (TLR4, MD-2, and CXCR7) more strongly
correlated with tumor size, lymph node metastasis and distant
metastasis than did each of the three markers alone. Thus,
recombination of TLR4, MD-2, and CXCR7 may prove to be
valuable prognostic markers for predicting the proliferation and
metastatic ability of colorectal carcinoma cells. An understanding
of the relationships between microbial signals and colorectal
carcinoma tissue might provide further clues for the development
of new therapeutic strategies.
Results
Exposure of TLR4 to LPS elevates CXCR7 expression in
colorectal carcinoma SW480 and Colo 205 cell lines
mRNA of colorectal carcinoma cell lines encoding TLR4
with its co-molecules, MD-2 were determined using RT-PCR.
The analysis of RT-PCR products showed that TLR4 and MD-2
were constitutively expressed in 4 out of 8 human colorectal
carcinoma cell lines, including Colo 205, RKO, SW480 and
SW620, whereas TLR4 and MD-2 were present respectively in
only two cell lines such as DLD-1 and HCT-29 (Fig. 1A). We
tested two cell lines(SW480 and Colo 205) with expression of
both TLR4 and MD-2 and one(HT-29) with expression of only
TLR4.
CXCR7 normally was minimally expressed, whereas CXCR4
was expressed at high level in SW480 cells. Real-time quantitative-
PCR and flow cytometry clearly indicated that the exposure of
SW480 cells expressing TLR4/MD-2 to LPS induced CXCR7
expression alterations significantly (p,0.001, p,0.001, resp.;
Fig. 1B, C). CXCR7 and CXCR4 were not expressed on Colo
205 cells. Similar results of LPS induced CXCR7 expression
alterations significantly appeared in Colo 205 cells (p,0.001,
p,0.001, resp. Fig. 1B, C).The natural peptide PMB is a well-
known and potent antibiotic that binds and neutralizes bacterial
endotoxin (LPS). In our study, PMB, the LPS inhibitor, inhibited
the LPS-induced CXCR7 expression alterations (Fig. 1B, C).
Maximal LPS effects were observed on CXCR7 protein
expression after 24 h exposure to a dose of 500 ng/ml,
representative examples of flow cytometry are shown (Fig. 1C).
In contrast to LPS induced CXCR7 expression alterations,
exposure of SW480 and Colo 205 cell lines to LPS had no effect
on CXCR4 expression (Fig. 1D).
In addition, CXCR7 and CXCR4 were not expressed on HT-
29 cells. Exposure of HT-29 cells with expression of only TLR4 to
LPS had no effect on CXCR7 or CXCR4 expression (data not
shown).
Knockdown of MD-2 inhibits LPS-mediated CXCR7
expression
In order to investigate the role of MD-2 in LPS-mediated
CXCR7 expression, we subjected SW480 and Colo 205 cell lines
expressing TLR4/MD-2 to transient transfection with the siRNA
specific for the MD-2 gene. 2 cell lines transfected with the MD-2
siRNA sequence exhibited a marked reduction in the abundance of
theendogenousMD-2mRNAandprotein levelcomparedwith that
in cells transfected with the negative control sequence (Fig. 2A).
Incubation of SW480 and Colo 205 cell lines transfected with
the MD-2 siRNA sequence with LPS did not reveal an increase in
CXCR7 mRNA and protein expression. In contrast, transfection
with the negative control sequence in cells resulted in a marked
increase in CXCR7 expression in response to LPS (p=0.001,
p=0.002, resp.; Fig. 2B). These results suggest that MD-2 is
essential for LPS-induced CXCR7 expression alteration.
CXCR7 mediated by LPS modulates tumor cell
proliferation and migration
Subsequently, we used a novel CXCR7-specific antagonist
CCX771 and an endogenous CXCR7 ligand (CXCL12) to
investigate the role of CXCR7 in regulating CXCL12-mediated
colorectal carcinoma cell proliferation, apoptosis and migration.
Incubation with LPS, the growth and viability of SW480 and
Colo 205 cell lines for 24 h and 48 h in the presence or absence
(control) of CXCL12 were examined. Because CXCR4 expressed
on SW480 cells is another receptor for CXCL12, SW480 cells were
pretreated(1 h)witha CXCR4antagonistAMD3100insomeofthe
experiments. Upon CXCL12 stimulation, SW480 cells pretreated
with AMD3100 proliferated significantly after 48 h (p,0.001,
p,0.001, resp.; Fig. 3A). In addition, SW480 cells pretreated with
CCX771 proliferated significantly after 48 h (p=0.001, p=0.015,
resp.; Fig. 3A). However, the proliferative effect of CXCR7 is more
than that of CXCR4 (p,0.001; Fig. 3A). At the same time, though
CXCR4 was not expressed in Colo 205 cells incubated with LPS,
CXCR7 significantly induced proliferation in Colo 205 cells
( p=0.003; Fig. 3A). The proliferative effect of CXCR7 was blocked
by a CXCR7 antagonist CCX771 (p,0.001; Fig. 3A).
No difference in apoptosis was detected in SW480 and Colo 205
cell lines grown with or without CXCL12 for up to 48 h, as
demonstrated by the annexin V and propidium iodide binding
assays (Fig. 3B). Therefore, CXCR7 expressed on colorectal
carcinoma cells results in cell proliferation, but may not exert an
antiapoptotic effect.
We also performed transwell migration assays to determine
whether CXCR7 induces migration of colorectal carcinoma cells.
After 24 h of incubation with LPS, not only CXCR7 but also
CXCR4 expressed in SW480 cells significantly induced migration
in the presence of CXCL12 (p,0.001, p,0.001, resp.; Fig. 3C).
However, there was no significant difference in migration effect of
CXCR7 and CXCR4 (p=0.102; Fig. 3C). Incubated with LPS,
CXCR7 significantly induced migration in Colo 205 cells
unexpressed CXCR4 (p,0.001; Fig. 3C). The migration effect
of CXCR7 was blocked by a CXCR7 antagonist CCX771
(p,0.001; Fig. 3C).
Taken together, these findings suggest that CXCR7 may
significantly uphold colorectal carcinoma cell proliferation and
promote cell migration.
TLR4, MD-2, and CXCR7 are expressed in human
colorectal carcinoma tissues
To further substantiate the growth-promoting and pro-migration
effects of CXCR7 mediated by TLR4, we investigated the
TLR4/CXCR7 in Human Colorectal Carcinoma
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expression using immunohistochemistry in human colorectal
carcinoma tissues. TLR4, MD-2 and CXCR7 exhibited mostly
cytoplasmic and plasmalemmal staining in colorectal carcinoma
tissues (Fig. 4D, E, F). Normal tissue adjacent to tumor cells showed
negative or occasionally weak staining that was mostly cytoplasmic
(Fig. 4A, B, C). The differences in expression of the three molecules
(TLR4, MD-2 and CXCR7) between normal colorectal tissues and
colorectal carcinoma tissues were all found to be statistically
significant (p,0.001, p,0.001, p=0.034, resp.; Table 1).
Figure 2. Knockdown effect of MD-2 on exposure of TLR4 to LPS in SW480 and Colo 205 cell lines. A, SW480 and Colo 205 cell lines were
transfected transiently with siRNA or negative control sequence(NC). SW480 and Colo 205 cell lines transfected with the MD-2 siRNA sequence
exhibited a marked reduction in MD-2 mRNA and protein level compared with NC. B, After LPS treatment, flow cytometry and real-time quantitative-
PCR were performed. Knockdown of MD-2 inhibited LPS-mediated CXCR7 expression.
doi:10.1371/journal.pone.0027399.g002
Figure 1. LPS-TLR4-MD-2 induced CXCR7 expression alteration in colorectal carcinoma cell line. A, Reverse transcriptase (RT)-PCR
analysis (TLR4 and MD-2) on RNA isolated from 8 human colorectal carcinoma cell lines. B, LPS induced time- and dose-dependent CXCR7 and CXCR4
protein expression alterations. SW480 and Colo 205 cell lines were incubated with LPS (500 ng/ml) in the presence or absence of PMB (500 mg/ml),
representative flow cytometric analysis of CXCR7 expression alterations were showed. C, LPS exposure induced a significant CXCR7 expression
increase in total RNA conten. D, Exposure of SW480 and Colo 205 cell lines to LPS (500 ng/ml) had no effect on CXCR4 expression.
doi:10.1371/journal.pone.0027399.g001
TLR4/CXCR7 in Human Colorectal Carcinoma
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clinicopathologic features
As shown in Table 1, there is a statistically significant
correlation between TNM stage and TLR4 expression
(p=0.017), MD-2 expression (p=0.013) or CXCR7 expression
(p=0.029). We also found that the increased expression is
significantly associated with advanced histological grade
(p=0.002 for TLR4, p=0.010 for MD-2 and p=0.004 for
CXCR7). There were no statistically significant differences in
these molecules with regard to patient age and sex.
Single or combined high expression of TLR4, MD-2 and
CXCR7 are associated with tumor size and lymph node
metastasis
The incidence of tumor size tended to be higher in cases with
high rather than low expression of TLR4, MD-2, and CXCR7
(p=0.003, p,0.001, p=0.013, resp.; Table 1). Notably, when
compared with high expression of these single markers, concom-
itant and high expression of any two of the three markers was
statistically significantly associated with tumor size in patients with
colorectal carcinoma (p,0.001 for TLR4/MD-2, p=0.001 for
TLR4/CXCR7 and p,0.001 for MD-2/CXCR7; Table 2). We
also found that combined high expression of all TLR4, MD-2, and
CXCR7 was significantly associated with tumor size, when
compared with other combinations (p=0.037; Table 2).
At the same time, the incidence of lymph node metastasis
tended to be higher in patients with colorectal carcinoma with
high rather than low expression of TLR4, MD-2, or CXCR7
(p=0.001, p=0.012, p,0.001, resp.; Table 1). After adjusting for
age, sex, tumor size and histologic grade, the risk of lymph node
metastasis was significantly associated with CXCR7 (OR adjust-
ed=14.06; 95% CI, 1.09–180.50; Table 3). As shown in Table 2,
there were statistically significant differences in high expression of
these single molecules, and high expression of two of the three
molecules TLR4/MD-2, TLR4/CXCR7, TLR4/CXCR7 with
regard to lymph node metastasis in patients with colorectal
carcinoma (p,0.001, p,0.001, p=0.001, resp.). Combined high
expression of all three molecules was significantly associated with
lymph node metastasis in patients as compared with cases not
showing such expression (p=0.002; Table 2).
In addition, the incidence of distant metastasis tended to be
higher in patients with colorectal carcinoma with high rather than
low expression of TLR4 or MD-2 (p=0.003, p=0.027, resp.;
Table 1). Moreover, there are statistically significant differences in
high expression of single TLR4, MD-2, or CXCR7 molecules, and
high expression of both of TLR4/CXCR7, or MD-2/CXCR7
molecules with regard to distant metastasis in patients with
colorectal carcinoma (p=0.009, p=0.001, resp.; Table 2). How-
ever, this result did not apply in the case of combination of TLR4/
MD-2 (p=0.081; Table 2). Combined high expression of all three
molecules is significantly associated with distant metastasis in
patients with colorectal carcinoma as compared with cases of high
expression in fewer than all three (p=0.042; Table 2).
Discussion
In this study, we show that LPS-TLR4-MD-2 induced CXCR7
expression alteration in the colorectal carcinoma SW480 and Colo
205 cell lines. CXCR7 mediated by TLR4 modulated tumor cell
proliferation and migration. However, exposure of SW480 and
Colo 205 cell lines to LPS had no effect on CXCR4 expression.
Furthermore, higher rates of TLR4, MD-2, and CXCR7
expression were found in colorectal carcinoma tissues than in
normal tissues. There was a statistically significant correlation
between single TLR4, MD-2, and CXCR7 expression levels and
human colorectal carcinoma TNM stage, advanced histological
grade, tumor size and lymph node metastasis. Furthermore, it was
demonstrated that concomitant expression of the three molecules
TLR4, MD-2 and CXCR7 is associated with increased carcinoma
growth and metastasis potential in human colorectal carcinoma.
The link between inflammation and cancer suggests that the
mechanisms contributing to inflammation may also be critical for
tumor formation and progression. TLRs comprise a group of
pattern recognition receptors which can sense pathogen invasion.
TLR4 is expressed in a variety of tumors, and TLR4 activation
can promote development and progression, apoptosis resistance,
invasion, metastasis of tumors and tumor immune escape [16–17].
Among all the TLR4 accessory molecules, MD-2 is the only one
that is absolutely required for the response to LPS [18–20].
Figure 4. Representative examples of immunohistochemical
staining of TLR4, MD-2, and CXCR7 in colorectal carcinoma
tissues (original magnification 1006). Positive staining was
observed as a dark brown color. Normal colorectal tissues showed
negative immunohistochemical staining of TLR4 (A), MD-2 (B), and
CXCR7 (C), and colorectal carcinoma tissues showed strong staining of
TLR4 (D), MD-2 (E), and CXCR7 (F).
doi:10.1371/journal.pone.0027399.g004
Figure 3. Proliferation, apoptosis and migration of CXCR7-positive SW480 and Colo 205 cell lines incubated with LPS. A, Incubation
with LPS, SW480 cell line pretreated with AMD3100 (10 mg/ml) proliferated significantly in response to CXCL12 (100 ng/ml; 48 h), Colo 205 cell line
also proliferated significantly in response to CXCL12. B, CXCL12 activation of its receptor CXCR7 did not exert an antiapoptotic effect. C, Pretreatment
with AMD3100, SW480 cell line migrated significantly more in response to CXCL12 after 24 h of incubation with LPS, Colo 205 cell line also migrated
significantly in response to CXCL12.
doi:10.1371/journal.pone.0027399.g003
TLR4/CXCR7 in Human Colorectal Carcinoma
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TLR4–MD-2 activity. Once LPS binds to TLR4 two signaling
pathways are activated: a MyD88-dependent pathway and a
MyD88-independent pathway. Based on studies using macro-
phages, these pathways are responsible for expression of NF-kB/
pro-inflammatory cytokines [21–23], can alter some cell functions:
cytoprotection, apoptosis, etc. In our present work, knockdown of
MD-2 in SW480 and Colo 205 cell lines has indeed provided
evidence that MD-2 is indispensable for TLR4 signaling.
Simultaneously, LPS had no effect on CXCR7 or CXCR4
expression of HT-29 cells not expressing MD2, with expression of
only TLR4. Moreover, the differences in expression of TLR4 and
MD-2 between normal colorectal tissues and colorectal carcinoma
tissues were all found to be statistically significant. Increased
expression of TLR4 and MD-2 was significantly associated with
TNM stage and advanced histological grade. Concomitant and
high expression of both markers TLR4/MD-2 was more
predictive of tumor size and lymph node involvement.
The development of metastasis is complex, requiring multiple
individual steps to successfully establish a tumor at a secondary
site. The process requires a tumor cell to acquire the ability of
proliferation, anti-apoptosis, migration and invasion, et al.
Increasing evidence suggests that chemokines and their receptors
are closely related to the mediation of inflammation, chemotaxis of
white blood cells and tumor biology. CXCR4/CXCL12, induced
by pro-inflammatory cytokines plays a role in metastasis of tumors
by inducing chemotactic, proliferative and invasive response [24].
The second chemokine receptor of CXCL12, CXCR7 was
formerly known as RDC1 [25]. As a membrane associated
receptor protein, CXCR7 is expressed on the surface of many
tumor cells [26–28], activated endothelial cells, and fetal liver cells,
but rarely in other normal cells. There is growing discussion about
CXCR7 enhancing tumor growth and migration through various
signaling pathways [26–27]. However, some scientists consider
that CXCR7 is a non-signaling receptor (decoy receptor) [28],
which binds the ligands CXCL12 and ITAC/CXCL11, does not
activate typical Gai pathways of a chemokine receptor that would
result in GTP hydrolysis or calcium mobilization [27]. Therefore,
we became interested in the role of the CXCR7/CXCL12 axis in
the biologic processes of colorectal carcinoma. Moreover, we tried
to verify the relationship between TLR4-MD-2 and CXCR7,
which has not been previously investigated.
Our data showed a marked increase of CXCR7 expression in a
TLR4/MD-2 positive colorectal carcinoma SW480 and Colo 205
Table 1. Correlation of TLR4, MD-2, and CXCR7 expression with clinicopathologic features in colorectal carcinoma.
Clinicopathologic Case No. TLR4 expression P value MD2 expression P value CXCR7 expression P value
parameters Low High Low High Low High
Total cases 66 31 35 20 46 47 19
Age
#60 30 12 18 p=0.3 8 22 p=0.557 22 8 p=0.728
.60 36 19 17 12 24 25 11
Tissue type
Normal colorectal tissue 20 20 0 p,0.001 15 5 p,0.001 19 1 p=0.034
Colon carcinoma 66 31 35 20 46 47 19
Sex
Male 34 18 16 p=0.316 9 25 p=0.485 20 14 p=0.022
Female 32 13 19 11 21 27 5
Tumor size
#5c m 2 6 1 8 8 p=0.003 15 11 p,0.001 23 3 p=0.013
.5 cm 40 13 27 5 35 24 16
TNM stage
I2 2 0 p=0.017 2 0 p=0.013 2 0 p=0.029
II 34 21 13 14 20 29 5
III 18 5 13 2 16 9 9
IV 12 3 9 2 10 7 5
Histologic grade
I6 6 0 p=0.002 5 1 p=0.012 6 0 p=0.004
II 50 24 26 13 37 38 12
III 10 1 9 2 8 3 7
Lymph node metastasis
Negative 37 24 13 p,0.001 16 21 p=0.010 33 4 p,0.001
Positive 29 7 22 4 25 14 15
Distant metastasis
Negative 51 29 22 p=0.003 19 32 p=0.027 38 13 p=0.335
Positive 15 2 13 1 14 9 6
doi:10.1371/journal.pone.0027399.t001
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mediated time- and dose-dependent CXCR7 expression alter-
ations. Furthermore, exposure of SW480 and Colo 205 cell lines to
LPS had no effect on CXCR4 expression. CXCR7 and CXCR4
expressed on tumor cells significantly induced proliferation and
migration in the presence of CXCL12. However, in this study, the
proliferative effect of CXCR7 is more than that of CXCR4, there
was no significant difference in migration effect of CXCR7 and
CXCR4. Then, the differences in expression of CXCR7 between
normal colorectal tissues and colorectal carcinoma tissues were
found to be statistically significant. There was a statistically
significant correlation between CXCR7 expression and TNM
stage and advanced histological grade. We also found CXCR7 was
an independent predictor of metastasis - independent of size and
histological grade.
Notably, the present study suggests that TLR4, MD-2, and
CXCR7 are highly expressed in colorectal carcinoma. Further-
more, the concomitant and high expression of all three markers is
significantly associated with tumor size, lymph node metastasis and
distant metastasis. However, more evidence will be needed to
identify the mechanism of TLR4-MD-2 activation through
CXCR7-mediated signaling and their synergistic role in tumors.
In summary, we have shown that the alteration of CXCR7
expression mediated by TLR4 promotes tumor cell proliferation
and migration in human colorectal carcinoma. This suggests that
infective states are not merely related to surrounding inflammatory
products but also to an effect of LPS on occurrence and
development of colorectal carcinoma. Crosstalk among the three
proteins TLR4, MD-2, or CXCR7 may be closely related to
promotion of tumor growth and metastasis. Inhibition of TLR4,
MD-2, or CXCR7 may be an effective adjuvant therapy for
colorectal carcinoma.
Materials and Methods
Cell lines and culture
The following human colorectal carcinoma cell lines were from
American type culture collection (ATCC): Caco-2, HT-29, DLD-
1, Colo 205, HCT 116, RKO, SW480 and SW620.
Caco-2 cells were cultured in Eagle’s Minimum Essential
Medium (Catalog No. 30-2003, ATCC, USA) supplemented with
Table 3. The simple and multiple logistic regression model
analyzing the predictors of colorectal carcinoma lymph node
metastasis.
Variable
Simple logistic
regression Multiple logistic regression*
OR 95% CI OR 95% CI
TLR4 5.80 2.00–17.18 8.77 1.18–65.08
MD2 4.76 1.38–16.45 2.65 0.23–31.04
CXCR7 8.84 2.49–31.41 14.06 1.09–180.50
*ORs and 95% CIs were calculated by unconditional logistic regression after
adjusting for age, sex, tumor size and histologic grade.
doi:10.1371/journal.pone.0027399.t003
Table 2. Correlation of combined high expression of TLR4, MD-2, and CXCR7 with tumor size and metastasis.
Tumor size p -value Lymph node metastasis p value Distant metastasis p value
#5c m ( % ) .5 cm(%) Negative(%) Positive(%) Negative(%) Positive(%)
TLR4/MD2
(1)Both TLR4/MD2 low
expression
13(81) 3(19) p,0.001 14(87) 2(13) p,0.001 15(94) 1(6) p=0.081
(2)One of TLR4/MD2
high expression
12(34) 23(66) (2) versus (3) 21(62) 13(38) (2) versus (3) 27(77) 8(23) (2) versus (3)
(3)Both TLR4/MD2
high expression
1(7) 14(93) p=0.076 2(13) 13(87) P=0.002 9(60) 6(40) p=0.304
TLR4/CXCR7
(1)Both TLR4/CXCR7
low expression
14(67) 7(33) p=0.001 19(90) 2(10) p,0.001 21(100) 0(0) p=0.009
(2)One of TLR4/CXCR7
high expression
12(34) 23(66) (2) versus (3) 18(53) 16(47) (2) versus (3) 24(69) 11(31) (2) versus (3)
(3)Both TLR4/CXCR7
high expression
0(0) 10(100) p=0.042 0(0) 10(100) p=0.003 6(60) 4(40) p=0.710
MD2/CXCR7
(1)Both MD2/CXCR7
low expression
11(100) 0(0) p,0.001 11(100) 0(0) p,0.001 11(100) 0(0) p,0.001
(2)One of MD2/CXCR7
high expression
11(38) 18(62) (2) versus (3) 18(62) 11(38) (2) versus (3) 26(90) 3(10) (2) versus (3)
(3)Both MD2/CXCR7
high expression
4(15) 22(85) p=0.061 8(31) 18(69) p=0.020 14(54) 12(46) p=0.003
TLR4/MD2/CXCR7
(1)Fewer than TLR4,MD2
and CXCR7 high expression
26(44) 33(56) p=0.037 37(64) 21(36) p=0.002 48(81) 11(19) p=0.042
(2)All of TLR4,MD2 and
CXCR7 high expression
0(0) 7(100) 0(0) 7(100) 3(43) 4(57)
doi:10.1371/journal.pone.0027399.t002
TLR4/CXCR7 in Human Colorectal Carcinoma
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e2739920% fetal bovine serum (FBS), penicillin (100 U/ml), and
streptomycin (100 mg/ml) at 37uC and in 5% CO2. HT-29 cells
and HCT 116 cells were cultured in McCoy’s 5a Medium Modified
(Catalog No. 30-2007, ATCC, USA) supplemented with 10% FBS,
penicillin(100 U/ml),andstreptomycin(100 mg/ml)at37uCandin
5% CO2. DLD-1 cells and Colo 205 cells were cultured in RPMI-
1640 Medium (Catalog No. 30-2001, ATCC, USA) supplemented
with 10% FBS, penicillin (100 U/ml), and streptomycin (100 mg/
ml) at 37uC and in 5% CO2. RKO cells were cultured in Eagle’s
Minimum Essential Medium (Catalog No. 30-2003, ATCC, USA)
supplemented with 10% FBS, penicillin (100 U/ml), and strepto-
mycin (100 mg/ml) at 37uC and in 5% CO2. SW480 cells and
SW620 cells were cultured in Leibovitz’s L-15 Medium (Catalog
No. 41300039, Gibco, Invitrogen, Life Technologies, USA)
supplemented with 10% FBS, penicillin (100 U/ml), and strepto-
mycin (100 mg/ml) at 37uC and in 5% CO2.
Patients and Specimens
This research was approved by Medical Ethics Committee of
The First Affiliated Hospital of Bengbu Medical College. All
participants gave informed written consent before participating in
the study. Colorectal carcinoma samples were collected from 66
patients undergoing curative-intent surgery at the Department of
Surgery, The First Affiliated Hospital of Bengbu Medical College,
and the Department of Surgery, Renji Hospital, Shanghai Jiao
Tong University School of Medicine between 2005 and 2011.
There were also 20 normal colorectal tissue samples adjacent to
colorectal carcinoma (used as controls). The histologic sections
were reviewed by two expert pathologists to verify the histologic
diagnosis. None of the patients had received any preoperative
treatment. Tumors were staged according to the American Joint
Committee on Cancer (AJCC) pathologic tumornode-metastasis
(TNM) classification. Informed consent was obtained from all
study subjects before sample collection and these samples were
used according to ethical standards.
Antibodies and other reagents
LPS (Catalog No. L6011) and Polymyxin B (PMB; Catalog
No. P4932), the LPS inhibitor, were from Sigma-Aldrich, USA.
Monoclonal anti-human TLR4 antibody (Clone ab22048),
monoclonal anti-human MD-2 antibody (Clone ab24182) were
from Abcam, England; monoclonal anti-human CXCR7 antibody
(Clone MAB4227) from R&D systems, USA; monoclonal anti-
human CXCR4 antibody (Clone 5555974) from BD, USA; a
CXCR4 antagonist (AMD3100) from Sigma-Aldrich, USA;
CXCL12 (Clone 2716-SD-025/CF) from R&D, USA. A CXCR7
antagonist (CCX771) was kindly provided by ChemoCentryx.
HRP-conjugated secondary antiserum (Clone A0216, Beyotime,
China) was used in Western blotting assay.
Reverse transcriptase (RT)-PCR and real-time
quantitative-PCR assay
Total RNA was isolated from colorectal carcinoma cell lines
using TRIzol (Invitrogen, USA) according to the manufacturer’s
instructions, and reverse transcribed. The primers for TLR4 were
59-TGCAATGGATCAAGGACCAGAGG-39 and 59-TGCAGC-
CAGCAAGAAGCATCAG-39. The primers for MD-2 were 59-
CCGAGGATCTGATGACGATT A-39 and 59-GGCTCCCA-
GAAATAGCTTCAA -39. The primers for CXCR7 were 59-
CACAGCACAGCCAGGAAGG-39 and 59-GTTCCCTGGC-
TCTGAGTAGTCGA-39. PCR products were analysed by
electrophoresis in 2% agarose gel stained with ethidium bromide.
The real-time quantitative-PCR reaction was performed using
SYBR Green master mix (ABI, Foster City, CA). GAPDH gene
was used as an endogenous control for sample normalization. The
primers for GAPDH were 59-GGATTTGGTCGTATTGGG-39
and 59-GGAAGATGGTGATGGGATT-39. Data were collected
and quantitatively analyzed on an ABI Prism 7900 sequence
detection system. Differences in the relative levels of three markers
normalized to GAPDH can be estimated by differences in the
ratios.
Flow cytometric assay
For in vitro studies of CXCR7 and CXCR4 expression
regulation, all cell lines were cultured in 2% FBS. After 12 h,
colorectal carcinoma SW480, Colo 205 and HT-29 cells were
treated with LPS in the presence or absence of PMB. Cultures
were trypsinized and 5610
5 cells were incubated for 1 h with a
monoclonal anti-human CXCR7 or CXCR4 antibody, and
analysed using a Becton Dickinson FACSCan with CellQuest
software. Cells from the SW480 and Colo 205 cell lines were
isolated and gated to exclude dead and GFP-negative cells so that
only cells that were GFP positive were analysed.
Transient transfection
A sequence of 19-nucleotide residues in length (GUGGGAGA-
GAUUUAAAGCA) specific to the human MD-2 cDNA (nucleo-
tide residues, 222–241) was selected for synthesis of a siRNA
(GenenPharma, USA). The siRNA was dissolved in DEPC water
and transfected into colorectal carcinoma SW480 and Colo 205 cell
lines with Lipofectamine 2000 (Invitrigen, USA). Effects of siRNA
for MD-2 was compared with those of a random siRNA sequence
(negative control sequence). The depletion of endogenous MD-2 by
the siRNA was confirmed by RT-PCR and Western blot.
Western blot analysis
Colorectal carcinoma SW480 and Colo 205 cell lines were lysed
in RIPA Lysis Buffer (Beyotime, China) supplemented with
protease inhibitor Cocktail (Catalog No. A7706_0001, Appli-
Chem, Germany). Protein concentration in the postnuclear lysates
was measured by BCA Protein Assay (Beyotime, China) and equal
amounts of protein lysates (60 mg) were loaded on 10% SDS-
PAGE. Gels were transferred to nitrocellulose using iBlot Dry
Blotting System (Invitrogen, USA). Filters were blocked with 5%
dry skimmed milk and blotted with the specific primary antibodies:
mouse monoclonal antibody to MD-2. Blots were then incubated
with the appropriate HRP-conjugated secondary antiserum, and
signal revealed with the WestPico chemiluminescence system
(Pierce). Filters were stripped for 10 min with ReBlot Plus Strong
Antibody Stripping Solution (Millipore).
Cell proliferation assay
Colorectal carcinoma SW480 and Colo 205 cell lines were
cultured in 96-well plates at an initial density of 2,000 cells per
well, in 100 ml of 1% FBS-medium without (control) or with
addition of CXCL12 (100 ng/ml). In some of the experiments,
SW480 cells were pretreated (1 h) with CCX771 (1 UM) and/or
AMD3100 (10 mg/ml), Colo 205 cells were pretreated (1 h) with
CCX771 (1 UM). After 24 h, and 48 h, effects of CXCL12 on cell
proliferation were determined by using a WST-1 Kit (Beyotime,
China). Each experimental condition was sampled in duplicate
and the experiments were repeated five times.
Apoptosis assay
Colorectal carcinoma SW480 and Colo 205 cell lines were
incubated in 1% FBS-medium without (control) or with addition
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were pretreated (1 h) with CCX771 (1 UM) or/and AMD3100
(10 mg/ml), Colo 205 cells were pretreated (1 h) with CCX771
(1 UM). After 24 h and 48 h, the cells were washed with
incubation buffer, and incubated for 30 min at room temperature
with 0.5 mg/ml propidium iodide (eBioscience, USA) and annexin
V-FITC (eBioscience, USA). 2610
5 cells were collected for each
sample by flow cytometry. Each experiment was repeated five
times.
Migration experiments
Colorectal carcinoma SW480 and Colo 205 cell lines were
resuspended in 1% FBS-medium of 5610
5 cells/ml, and seeded
into the upper chambers of Transwell inserts (Millipore). 1% FBS-
medium was added to the lower chambers, without (control) or
with addition of CXCL12 (100 ng/ml). In some of the
experiments, SW480 cells were pretreated (1 h) with CCX771
(1 UM) or/and AMD3100 (10 mg/ml), Colo 205 cells were
pretreated (1 h) with CCX771 (1 UM).. The migration was
carried out at 37uC and 5% CO2 for 24 h. After incubation, the
nonmigrated cells were removed from the upper surface of the
filters, and the migrated cells, adherent to the lower surface, were
counted (ten high-power fields/well). Each experiment was
repeated five times.
Immunohistochemistry assay
Sections were subjected to routine deparaffination and rehy-
dration. Antigen retrieval was achieved by microwaving in
0.01 mol/L citrate buffer for 10 min and then cooling for
30 min. The endogenous peroxidase activity was inhibited by
incubation with 3% hydrogen peroxide in methanol for 20 min
and nonspecific binding was blocked by incubation with 5%
bovine serum albumin in phosphate-buffered saline (PBS) at room
temperature. After three PBS washes, the specimens were reacted
overnight at 4uC with murine anti-human monoclonal antibodies:
anti-TLR4, anti-MD-2 and anti-CXCR7. After incubation with
rat anti-mouse-IgG2b-horseradish peroxidase, signal was devel-
oped with 3,30-diaminobenzidine tetrahydrochloride in Tris–HCl
buffer (pH 7.6) containing 0.02% hydrogen peroxide. The sections
were then counterstained with hematoxylin and mounted.
Negative controls were performed by replacing the primary
antibody with nonspecific IgG at the same concentration.
Interpretation and evaluation of immunohistochemical
results
Immunostaining was independently examined by two clinical
pathologists who were unaware of the patient outcome. For each
sample, five high-power fields (1006) were randomly selected.
Staining intensity and percentage of positive tumor cells were
assessed. The extent of the staining was categorized into five
semiquantitative classes based on the percentages of positive tumor
cells: 0 (,5% positive cells), 1 (6–25% positive cells), 2 (26–50%
positive cells), 3 (51–75% positive cells) and 4 (.75% positive
cells). The intensity of cytoplasmic and membrane staining was
also determined semiquantitatively on a scale of 0–3 as follows: 0
(negative), 1 (weakly positive), 2 (moderately positive) and 3
(strongly positive). A consensus score was assigned for each section
after discussion and careful review of all slides by the two
pathologists. Multiplication of the intensity and the percentage
scores gave rise to the final staining score: 0 (negative), + (1–4), ++
(5–8), and +++ (9–12). For statistical analysis, tumors having a final
staining score of negative or +, which showed a weak or moderate/
strong immunoreactivity were grouped into a low expression
group and were compared to tumors with scores of ++ or +++ as
the high expression group.
Statistical analysis
Differences were evaluated using Statistical Package for Social
Science software (version 16.0, SPSS Inc., Chicago, IL). The
association of staining intensity with clinicopathologic patterns was
assessed with the Chi square test and two-sided Fisher’s exact test
to determine the significance of the difference between the the
covariates. A logistic regression model was used to estimate odds
ratios (ORs) and 95%confidence intervals (CIs) for the association
between CXCR7 and ymph node metastases. All measurement
data are presented as mean 6 SEM. Statistical significance was
evaluated by one-way ANOVA, followed by least significant
difference (LSD) test. P values,0.05 were considered to be
statistically significant.
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